Literature DB >> 22470381

Oxidative stress in cystinosis patients.

Maria Helena Vaisbich1, Luciana Pache de Faria Guimaraes, Maria Heloisa Mazzola Shimizu, Antonio Carlos Seguro.   

Abstract

BACKGROUND/AIMS: Nephropathic cystinosis (NC) is a severe systemic disease and cysteamine improves its prognosis. Lysosomal cystine accumulation is the hallmark of cystinosis and is regarded as the primary defect due to mutations in the CTNS gene. However, there is great evidence that cystine accumulation itself is not responsible for all abnormalities observed in NC. Studies have demonstrated altered ATP metabolism, increased apoptosis, and cell oxidation. An increased number of autophagosomes and autophagic vacuoles have been observed in cystinotic fibroblasts and renal epithelial cells, suggesting that altered autophagy plays a role in NC, leading to increased production of reactive oxygen species. Therefore, cystinosis patients can be more susceptible to oxidative stress (OS) and it can contribute to the progression of the renal disease. Our goal was to evaluate a marker of OS (serum TBARS) in NC children, and to compare the results with those observed in healthy controls and correlated with renal function parameters.
METHODS: The study included patients aged under 18 years, with good adherence to the treatment and out of renal replacement therapy. The following parameters were evaluated: serum creatinine, BUN, creatinine clearance estimated by stature and serum TBARS levels.
RESULTS: We selected 20 patients aged 8.0 ±3.6 years and observed serum TBARS levels of 4.03 ±1.02 nmol/ml. Serum TBARS levels in the 43 healthy controls, aged 7.4 ±1.1 years, were 1.60 ±0.04 nmol/ml. There was a significant difference between the plasma TBARS levels among the 2 groups (p < 0.0001). We detected no significant correlation between plasma TBARS levels and renal function.
CONCLUSION: An increased level of serum TBARS in patients with NC was observed and this abnormality was not correlated with the renal function status degree. This is the first report that shows increased oxidative stress in serum of NC patients.

Entities:  

Keywords:  Biomarkers; Chronic kidney disease; Cysteamine; Cystinosis; End-stage renal disease; Oxidative stress; Thiobarbituric acid

Year:  2011        PMID: 22470381      PMCID: PMC3290844          DOI: 10.1159/000331445

Source DB:  PubMed          Journal:  Nephron Extra        ISSN: 1664-5529


Introduction

Nephropathic cystinosis is a severe systemic progressive disease. It involves several organs throughout life. First, the kidneys are affected by proximal tubular dysfunction and Fanconi's syndrome. During childhood, there is also frequent hypothyroidism and ocular involvement, leading to photophobia. Renal glomerular damage generally becomes apparent between 2 and 5 years of age and results in end-stage renal disease between 9 and 10 years of age, unless treatment with a cystine-depleting drug, cysteamine, is initiated early in life [1]. Patients without this treatment, besides presenting glomerular damage and chronic renal insufficiency, can also present pancreatic problems, e.g. diabetes mellitus and high levels of amylase, hepatic involvement, gastrointestinal complications, e.g. vomiting or gastric ulcers, muscular wasting and weakness, and various degrees of central nervous system involvement [1, 2]. However, although lysosomal cystine accumulation is the hallmark of cystinosis and is regarded as the primary defect due to mutations in the CTNS gene, there is great evidence that cystine accumulation itself is not responsible for all abnormalities observed in cystinosis. Several studies have recently demonstrated altered ATP metabolism, increased apoptosis, and cell oxidation. For the most part, these abnormalities were observed using cell models and are not necessarily mutually exclusive [3]. Moreover, an increased number of autophagosomes and autophagic vacuoles have been observed in cystinotic fibroblasts and renal epithelial cells, suggesting that altered autophagy also plays a role in cystinosis [4]. These observations were associated with structural mitochondrial abnormalities and increased production of reactive oxygen species (ROS). Taken together, these findings suggest that cystinosis patients can be more susceptible to oxidative stress, which can contribute to the progression of renal disease in cystinosis patients even when they show a good response to treatment with cysteamine [5, 6]. Our aim was to evaluate a marker of oxidative stress in pediatric cystinosis and compare the results obtained in cystinotic children with those observed in healthy normal controls. We also correlated the oxidative stress marker with renal function parameters in these patients. Of note, this is the first documentation of increased oxidative stress in the serum of cystinotic patients.

Patients and Methods

Patients

The study cohort was selected from cystinosis patients aged <18 years. Inclusion criteria were parental consent for participation in the study and good adherence to the treatment, including their attendance at the follow-up examinations and clinical evaluations, and no renal replacement therapy. Only patients with chronic kidney disease (CKD) in stage 1–4 (based on KDOQI guidelines [7]) were included. All patients selected had taken cysteamine at a recommended dosage of 60–90 mg/kg/day [5]. Sample collections to measure the parameters of the study were done at the time when patients were under metabolic and electrolyte control, and free of infections.

Methods

The following renal function parameters were evaluated: serum creatinine, BUN and creatinine clearance estimated by the Schwartz formula [8]. Serum levels of thiobarbituric acid-reactive substances (TBARS), which are markers of lipid peroxidation, were determined using the TBARS assay. In brief, 0.2 ml of serum sample was diluted in 0.8 ml of distilled water. Immediately thereafter, 1 ml of 17.5% trichloroacetic acid was added. Following the addition of 1 ml of 0.6% thiobarbituric acid, pH 2, the sample was placed in a boiling water bath for 15 min, after which it was allowed to cool. Subsequently, 1 ml of 70% trichloroacetic acid was added, and the mixture was incubated for 20 min. The sample was then centrifuged for 15 min at 2,000 r.p.m. The optical density of the supernatant was read at 534 nm against a reagent blank using a spectrophotometer. The quantity of TBARS was calculated using a molar extinction coefficient of 1.56 × 105M−1 cm−1. Serum levels of TBARS (expressed as nmol/ml [9]) were compared between patients and healthy controls, and associations between this parameter and parameters of renal function were assessed.

Statistical Analysis

Homogenous data are expressed as means ± SD, and non-homogenous data are expressed as medians (interquartile ranges). The independent sample t test was employed to compare serum levels of TBARS between the patients and healthy control children, and Pearson's correlation coefficient was used to correlate serum TBARS with renal function parameters. This study was approved by the local ethics committee. Informed consent was obtained from the parents of all children for participation in this study.

Results

We selected 20 cystinosis patients (6 females) aged 8.0 ± 3.6 years (mean ± SD) in CKD stage 1–4 with good adherence to the treatment comprising cysteamine. The distribution of the patients according to CKD stage is shown in table 1. The dosage of cysteamine was 72.06 ± 5.22 mg/kg/day and was divided every 6 h.
Table 1

Cystinosis patients (n = 20) according to CKD stage

CKD stage 19 patients
CKD stage 25 patients
CKD stage 35 patients
CKD stage 41 patient
Table 2 shows the results found in these cystinosis patients. In the 43 healthy controls aged 7.4 ± 1.1 years (mean ± SD), serum levels of TBARS were 1.60 ± 0.04 nmol/ml (mean ± SD); in cystinosis patients, serum TBARS levels were 4.03 ± 1.02 nmol/ml (mean ± SD). There was no statistical difference between patients and healthy controls regarding age, but there was a significant difference between the plasma TBARS levels between both groups (p < 0.0001).
Table 2

Parameters measured in the 20 cystinosis patients

Serum creatinine, μmol/l
 Median59.5
 Interquartile range39.6–93.0
 Geometric mean, log transformed61.0
BUN, mmol/l10.3 ± 5.7
eGFR (Schwartz formula), ml/min/1.73 m284.0 ± 41.5
Serum TBARS, nmol/ml4.03 ± 1.02
To determine the effect of renal function impairment on serum TBARS, we correlated this parameter with serum creatinine, BUN, creatinine clearance estimated by stature and CKD stage. No significant correlations between plasma TBARS and all these parameters were detected (fig. 1).
Fig. 1

Correlation between plasma TBARS and serum creatinine (a, c), BUN (b) and creatinine clearance estimated by stature [eGFR (Schwartz formula); d] in nephropathic cystinosis patients. a r = −0.04, p = 0.86. b r = 0.02, p = 0.93. c r = −0.10, p = 0.65. d r = 0.17, p = 0.46.

Discussion

Nephropathic cystinosis is a severe disease. Although cysteamine treatment improves its prognosis, renal failure is not completely abolished. Gahl et al. [6] emphasized that cysteamine is not 100% effective, even taking all appropriate steps, since some patients present extrarenal complications and renal failure at the age of 20 years. Likewise, Greco et al. [10] have also demonstrated that end-stage renal failure cannot be prevented in most patients but is only postponed to the 2nd or 3rd decade of life; late-onset complications ultimately develop in a substantial proportion of patients. Ergo, nephropathic cystinosis remains a challenge for the treating physician. Recently, several studies have demonstrated altered ATP metabolism, and increased apoptosis and cell oxidation in cystinosis [3]. In addition, increased autophagy is involved leading to increased ROS production [4]. Most of the studies have been conducted in cell models, but a study assessing oxidative stress in the serum of the patients has not been published to date. Therefore, our aim was to evaluate serum TBARS levels in pediatric cystinosis patients. Using this simple methodology, we observed that plasma TBARS, a biomarker of oxidative stress, was increased in patients with nephropathic cystinosis. The balance between oxidants and antioxidants is considerably distorted in patients with chronic renal insufficiency. Evidence suggests that ROS are not merely the consequence of treatment or progressing disease but also one of the causal agents of chronic renal impairment, and that oxidative stress can occur even in the absence of hemodialysis. Patients with uremia have diminished response to oxidative stress probably due to a decrease in the antioxidant capacity; the mechanisms underlying this decrease, however, remain to be elucidated [11]. However, in this study, we could not correlate TBARS levels with creatinine clearance, CKD stage, serum creatinine or BUN. Therefore, in cystinosis patients oxidative stress could be a result of the intrinsic mechanism of the disease [3]. Oxidative stress results in the formation of highly reactive and unstable lipid hydroperoxides, and decomposition of unstable peroxides derived from polyunsaturated fatty acids results in the formation of malondialdehyde, which is measured by the TBARS assay. However, a drawback of this assay is that there may be other sources of malondialdehyde. Thus, this test is not specific for lipid peroxidation. The limitations of our study are the small number of patients and the fact that TBARS is not the best oxidative stress marker. Although this is only a pilot study, it is of paramount importance since it is the first report proving that oxidative stress is increased in the serum of patients with cystinosis independent of the state of renal function. Therefore, we intend to assess more specific markers in future studies. This knowledge may have implications on the treatment of cystinosis patients, since oxidative stress is involved in the progression of renal disease, especially in these patients [11].
  11 in total

Review 1.  Cystinosis.

Authors:  William A Gahl; Jess G Thoene; Jerry A Schneider
Journal:  N Engl J Med       Date:  2002-07-11       Impact factor: 91.245

2.  A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine.

Authors:  G J Schwartz; G B Haycock; C M Edelmann; A Spitzer
Journal:  Pediatrics       Date:  1976-08       Impact factor: 7.124

Review 3.  Cystinosis coming of age.

Authors:  W A Gahl
Journal:  Adv Pediatr       Date:  1986

4.  Long-term outcome of nephropathic cystinosis: a 20-year single-center experience.

Authors:  Marcella Greco; Milena Brugnara; Marco Zaffanello; Anna Taranta; Anna Pastore; Francesco Emma
Journal:  Pediatr Nephrol       Date:  2010-08-29       Impact factor: 3.714

Review 5.  The pathogenesis of cystinosis: mechanisms beyond cystine accumulation.

Authors:  Martijn J Wilmer; Francesco Emma; Elena N Levtchenko
Journal:  Am J Physiol Renal Physiol       Date:  2010-09-08

6.  Mitochondrial autophagy promotes cellular injury in nephropathic cystinosis.

Authors:  Poonam Sansanwal; Benedict Yen; William A Gahl; Yewei Ma; Lihua Ying; Lee-Jun C Wong; Minnie M Sarwal
Journal:  J Am Soc Nephrol       Date:  2009-12-03       Impact factor: 10.121

7.  Evaluation of oxidative stress biomarkers in patients with chronic renal failure: a case control study.

Authors:  Marta Romeu; Rosa Nogues; Luís Marcas; Vanesa Sánchez-Martos; Miquel Mulero; Alberto Martinez-Vea; Jordi Mallol; Montserrat Giralt
Journal:  BMC Res Notes       Date:  2010-01-25

8.  National Kidney Foundation's Kidney Disease Outcomes Quality Initiative clinical practice guidelines for chronic kidney disease in children and adolescents: evaluation, classification, and stratification.

Authors:  Ronald J Hogg; Susan Furth; Kevin V Lemley; Ronald Portman; George J Schwartz; Josef Coresh; Ethan Balk; Joseph Lau; Adeera Levin; Annamaria T Kausz; Garabed Eknoyan; Andrew S Levey
Journal:  Pediatrics       Date:  2003-06       Impact factor: 7.124

9.  Report of a Brazilian multicenter study on nephropathic cystinosis.

Authors:  Maria Helena Vaisbich; Vera H Koch
Journal:  Nephron Clin Pract       Date:  2009-10-09

10.  Nephropathic cystinosis in adults: natural history and effects of oral cysteamine therapy.

Authors:  William A Gahl; Joan Z Balog; Robert Kleta
Journal:  Ann Intern Med       Date:  2007-08-21       Impact factor: 25.391

View more
  10 in total

1.  Lysosomal cystine accumulation promotes mitochondrial depolarization and induction of redox-sensitive genes in human kidney proximal tubular cells.

Authors:  Rodolfo Sumayao; Bernadette McEvoy; Philip Newsholme; Tara McMorrow
Journal:  J Physiol       Date:  2016-04-10       Impact factor: 5.182

2.  Cell-Based Phenotypic Drug Screening Identifies Luteolin as Candidate Therapeutic for Nephropathic Cystinosis.

Authors:  Ester De Leo; Mohamed A Elmonem; Sante Princiero Berlingerio; Marine Berquez; Beatrice Paola Festa; Roberto Raso; Francesco Bellomo; Tobias Starborg; Manoe Jacoba Janssen; Zeinab Abbaszadeh; Sara Cairoli; Bianca Maria Goffredo; Rosalinde Masereeuw; Olivier Devuyst; Martin Lowe; Elena Levtchenko; Alessandro Luciani; Francesco Emma; Laura Rita Rega
Journal:  J Am Soc Nephrol       Date:  2020-06-05       Impact factor: 10.121

3.  Cystinosin, the small GTPase Rab11, and the Rab7 effector RILP regulate intracellular trafficking of the chaperone-mediated autophagy receptor LAMP2A.

Authors:  Jinzhong Zhang; Jennifer L Johnson; Jing He; Gennaro Napolitano; Mahalakshmi Ramadass; Celine Rocca; William B Kiosses; Cecilia Bucci; Qisheng Xin; Evripidis Gavathiotis; Ana María Cuervo; Stephanie Cherqui; Sergio D Catz
Journal:  J Biol Chem       Date:  2017-05-02       Impact factor: 5.157

Review 4.  Roles of neutrophil reactive oxygen species (ROS) generation in organ function impairment in sepsis.

Authors:  Jiaqi Lu; Jingyuan Liu; Ang Li
Journal:  J Zhejiang Univ Sci B       Date:  2022-06-15       Impact factor: 5.552

5.  Evaluation of NACA and diNACA in human cystinosis fibroblast cell cultures as potential treatments for cystinosis.

Authors:  Emma Hector; Donald Cairns; G Michael Wall
Journal:  Orphanet J Rare Dis       Date:  2022-06-16       Impact factor: 4.303

6.  N-acetyl-cysteine is associated to renal function improvement in patients with nephropathic cystinosis.

Authors:  Luciana Pache de Faria Guimaraes; Antonio Carlos Seguro; Maria Heloisa Mazzola Shimizu; Letícia Aparecida Lopes Neri; Nairo Massakasu Sumita; Ana Carolina de Bragança; Rildo Aparecido Volpini; Talita Rojas Cunha Sanches; Fernanda Andrade Macaferri da Fonseca; Carlos Alberto Moreira Filho; Maria Helena Vaisbich
Journal:  Pediatr Nephrol       Date:  2013-12-11       Impact factor: 3.714

7.  Impairment of chaperone-mediated autophagy leads to selective lysosomal degradation defects in the lysosomal storage disease cystinosis.

Authors:  Gennaro Napolitano; Jennifer L Johnson; Jing He; Celine J Rocca; Jlenia Monfregola; Kersi Pestonjamasp; Stephanie Cherqui; Sergio D Catz
Journal:  EMBO Mol Med       Date:  2015-02       Impact factor: 12.137

8.  Multidisciplinary approach for patients with nephropathic cystinosis: model for care in a rare and chronic renal disease.

Authors:  Maria Helena Vaisbich; Carla Aline Fernandes Satiro; Deborah Roz; Debora de Almeida Domingues Nunes; Ana Carola H Lobo Messa; Camila Lanetzki; Juliana Caires de Oliveira Achili Ferreira
Journal:  J Bras Nefrol       Date:  2018-11-14

9.  Chaperone-Mediated Autophagy Upregulation Rescues Megalin Expression and Localization in Cystinotic Proximal Tubule Cells.

Authors:  Jinzhong Zhang; Jing He; Jennifer L Johnson; Farhana Rahman; Evripidis Gavathiotis; Ana Maria Cuervo; Sergio D Catz
Journal:  Front Endocrinol (Lausanne)       Date:  2019-02-01       Impact factor: 5.555

10.  DYNC1LI2 regulates localization of the chaperone-mediated autophagy receptor LAMP2A and improves cellular homeostasis in cystinosis.

Authors:  Farhana Rahman; Jennifer L Johnson; Jinzhong Zhang; Jing He; Kersi Pestonjamasp; Stephanie Cherqui; Sergio D Catz
Journal:  Autophagy       Date:  2021-10-13       Impact factor: 13.391

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.